Mona Clappier
Research Subjects
Mona Clappier has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Armen K. Kasabian
From Northwell Health, Zucker School of Medicine at Hofstra/Northwell
3 shared publications- Neil Tanna
From Northwell Health, Zucker School of Medicine at Hofstra/Northwell
3 shared publications Betsy Vasquez
Princeton Neuroscience Institute, Princeton, USA
2 shared publicationsBlake J. Laham
Princeton Neuroscience Institute, Princeton, USA
2 shared publications- Elizabeth Gould
Princeton Neuroscience Institute, Princeton University
2 shared publications Monica Hanani
Princeton Neuroscience Institute, Princeton, USA
2 shared publications
Latest Publications
- Open Access
- 8 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Author Correction: The estrous cycle modulates early-life adversity effects on mouse avoidance behavior through progesterone signaling
- 8 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessAuthor Correction: The estrous cycle modulates early-life adversity effects on mouse avoidance behavior through progesterone signaling
- Open Access
- 7 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
The estrous cycle modulates early-life adversity effects on mouse avoidance behavior through progesterone signaling
Early-life adversity (ELA) increases the likelihood of neuropsychiatric diagnoses, which are more prevalent in women than men. Since changes in reproductive hormone levels can also increase the probability of anxiety disorders in women, we examined the effects of ELA on adult female mice across the estrous cycle. We found that during diestrus, when progesterone levels are relatively high, ELA mice exhibit increased avoidance behavior and increased theta oscillation power in the ventral hippocampus (vHIP). We also found that diestrus ELA mice had higher levels of progesterone and lower levels of allopregnanolone, a neurosteroid metabolite of progesterone, in the vHIP compared with control-reared mice. Progesterone receptor antagonism normalized avoidance behavior in ELA mice, while treatment with a negative allosteric modulator of allopregnanolone promoted avoidance behavior in control mice. These results suggest that altered vHIP progesterone and allopregnanolone signaling during diestrus increases avoidance behavior in ELA mice.
- 7 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
Open AccessThe estrous cycle modulates early-life adversity effects on mouse avoidance behavior through progesterone signaling
Early-life adversity (ELA) increases the likelihood of neuropsychiatric diagnoses, which are more prevalent in women than men. Since changes in reproductive hormone levels can also increase the probability of anxiety disorders in women, we examined the effects of ELA on adult female mice across the estrous cycle. We found that during diestrus, when progesterone levels are relatively high, ELA mice exhibit increased avoidance behavior and increased theta oscillation power in the ventral hippocampus (vHIP). We also found that diestrus ELA mice had higher levels of progesterone and lower levels of allopregnanolone, a neurosteroid metabolite of progesterone, in the vHIP compared with control-reared mice. Progesterone receptor antagonism normalized avoidance behavior in ELA mice, while treatment with a negative allosteric modulator of allopregnanolone promoted avoidance behavior in control mice. These results suggest that altered vHIP progesterone and allopregnanolone signaling during diestrus increases avoidance behavior in ELA mice.
- 21 December 2021
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 149 (1) , 262-263
Discussion: A Guide to Industry Payments and an Algorithm for Their Management
- 21 December 2021
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 149 (1) , 262-263
Discussion: A Guide to Industry Payments and an Algorithm for Their Management
- 9 September 2021
- Published by Georg Thieme Verlag KG in Journal of Reconstructive Microsurgery
- Vol. 38 (05) , 390-394
Conflict of Interest at Microsurgery Conferences: Disclosure of Its Extent and Nature
Background Industry relationships and conflicts of interest can impact research funding, topics, and outcomes. Little research regarding the role of biomedical companies at microsurgery conferences is available. This study evaluates the role of industry at conferences by comparing payments received by speakers at the American Society for Reconstructive Microsurgeons (ASRM) meeting with those received by speakers at the American Society of Aesthetic Plastic Surgeons (ASAPS) meeting, the American Society of Plastic Surgeons (ASPS) meeting, and an average plastic surgeon. It also compares payments made by different companies. Methods General payments received by speakers at the 2017 ASAPS, ASPS, and ASRM conferences were collected from the Open Payments Database. Mean payments received at each conference were calculated and the Mann–Whitney U test evaluated differences between conference speakers and the average plastic surgeon. The total amount of payments from each company was collected through the Open Payments Database, and Z-tests identified which companies paid significantly more than others. Results The mean (and median) general payments made to conference speakers at ASAPS (n = 75), ASPS (n = 247), and ASRM (n = 121) were $75,577 ($861), $27,562 ($1,021), and $16,725 ($652), respectively. These payments were significantly greater (p < 0.001 for all) than those of the average plastic surgeon ($4,441 and $327), but not significantly different from each other. Allergan contributed significantly more than other companies to speakers at ASPS and ASAPS, while LifeCell Corporation, Zimmer Biomet Holdings, and Axogen contributed significantly more to speakers at ASRM. Conclusion Payments to physicians at ASRM were significantly higher than those of an average plastic surgeon but not significantly different from those of speakers at ASAPS and ASPS. Certain companies paid significantly more than their peers at each conference. Given these findings, speakers should strive to make clear the nature and extent of their conflicts of interest when presenting at conferences.
- 9 September 2021
- Published by Georg Thieme Verlag KG in Journal of Reconstructive Microsurgery
- Vol. 38 (05) , 390-394
Conflict of Interest at Microsurgery Conferences: Disclosure of Its Extent and Nature
Background Industry relationships and conflicts of interest can impact research funding, topics, and outcomes. Little research regarding the role of biomedical companies at microsurgery conferences is available. This study evaluates the role of industry at conferences by comparing payments received by speakers at the American Society for Reconstructive Microsurgeons (ASRM) meeting with those received by speakers at the American Society of Aesthetic Plastic Surgeons (ASAPS) meeting, the American Society of Plastic Surgeons (ASPS) meeting, and an average plastic surgeon. It also compares payments made by different companies. Methods General payments received by speakers at the 2017 ASAPS, ASPS, and ASRM conferences were collected from the Open Payments Database. Mean payments received at each conference were calculated and the Mann–Whitney U test evaluated differences between conference speakers and the average plastic surgeon. The total amount of payments from each company was collected through the Open Payments Database, and Z-tests identified which companies paid significantly more than others. Results The mean (and median) general payments made to conference speakers at ASAPS (n = 75), ASPS (n = 247), and ASRM (n = 121) were $75,577 ($861), $27,562 ($1,021), and $16,725 ($652), respectively. These payments were significantly greater (p < 0.001 for all) than those of the average plastic surgeon ($4,441 and $327), but not significantly different from each other. Allergan contributed significantly more than other companies to speakers at ASPS and ASAPS, while LifeCell Corporation, Zimmer Biomet Holdings, and Axogen contributed significantly more to speakers at ASRM. Conclusion Payments to physicians at ASRM were significantly higher than those of an average plastic surgeon but not significantly different from those of speakers at ASAPS and ASPS. Certain companies paid significantly more than their peers at each conference. Given these findings, speakers should strive to make clear the nature and extent of their conflicts of interest when presenting at conferences.
- 29 June 2021
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 148 (1) , 12e-13e
Discussion: Understanding the Relationship between Breast Reconstruction Subtype and Risk of Financial Toxicity: A Single-Institution Pilot Study
- 29 June 2021
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 148 (1) , 12e-13e
Discussion: Understanding the Relationship between Breast Reconstruction Subtype and Risk of Financial Toxicity: A Single-Institution Pilot Study
- 2 November 2019
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 34 (21) , 3568-3573
Complications of operative vaginal delivery and provider volume and experience
Objective: To evaluate associations between operative vaginal delivery complications and provider experience (operative vaginal delivery volume and time since residency). Methods: We included all operative vaginal deliveries between 2008 and 2014 at a tertiary care teaching hospital, stratified into forceps-assisted and vacuum-assisted deliveries. Complications included severe perineal lacerations (3rd and 4th degree) and neonatal injuries (subgaleal/subdural/cerebral hemorrhage, facial nerve injury, and scalp injury), which were identified by International Classification Diagnosis-9 codes. Providers were categorized by operative vaginal delivery volume (mean annual forceps- or vacuum-assisted deliveries over the study interval) and time since residency. Regression analyses were used to compare complication rates by provider volume and time since residency, adjusting for potential confounders, using 0–1 deliveries per year and 10 forceps per year (aOR 0.50 [95%CI 0.30–0.81]) and at 15–19 years (aOR 0.45 [95% CI 0.22–0.94], and ≥25 years (aOR 0.45 [0.27–0.73]) since residency. There were no associations with neonatal injuries. Among vacuum-assisted deliveries, severe perineal injury decreased at ≥25 years since residency (aOR 0.35 [95%CI 0.17–0.74], with no association with provider volume. Neonatal injury decreased at 5–9 years (aOR 0.53 [95%CI 0.30–0.93]), and 15–19 years since residency (aOR 0.53 [95%CI 0.29–0.97]), due to differences in scalp injuries. Neonatal injuries other than scalp injury were rare. Conclusion: Severe perineal lacerations decreased with increasing operative vaginal delivery experience, primarily among forceps-assisted vaginal delivery. Providers >5 years since residency may have lower scalp injury with vacuums, but this cohort was largely underpowered for neonatal injury.
- 2 November 2019
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 34 (21) , 3568-3573
Complications of operative vaginal delivery and provider volume and experience
Objective: To evaluate associations between operative vaginal delivery complications and provider experience (operative vaginal delivery volume and time since residency). Methods: We included all operative vaginal deliveries between 2008 and 2014 at a tertiary care teaching hospital, stratified into forceps-assisted and vacuum-assisted deliveries. Complications included severe perineal lacerations (3rd and 4th degree) and neonatal injuries (subgaleal/subdural/cerebral hemorrhage, facial nerve injury, and scalp injury), which were identified by International Classification Diagnosis-9 codes. Providers were categorized by operative vaginal delivery volume (mean annual forceps- or vacuum-assisted deliveries over the study interval) and time since residency. Regression analyses were used to compare complication rates by provider volume and time since residency, adjusting for potential confounders, using 0–1 deliveries per year and 10 forceps per year (aOR 0.50 [95%CI 0.30–0.81]) and at 15–19 years (aOR 0.45 [95% CI 0.22–0.94], and ≥25 years (aOR 0.45 [0.27–0.73]) since residency. There were no associations with neonatal injuries. Among vacuum-assisted deliveries, severe perineal injury decreased at ≥25 years since residency (aOR 0.35 [95%CI 0.17–0.74], with no association with provider volume. Neonatal injury decreased at 5–9 years (aOR 0.53 [95%CI 0.30–0.93]), and 15–19 years since residency (aOR 0.53 [95%CI 0.29–0.97]), due to differences in scalp injuries. Neonatal injuries other than scalp injury were rare. Conclusion: Severe perineal lacerations decreased with increasing operative vaginal delivery experience, primarily among forceps-assisted vaginal delivery. Providers >5 years since residency may have lower scalp injury with vacuums, but this cohort was largely underpowered for neonatal injury.